Rabies vaccines have existed for well over a century, and modern versions are both safe and highly effective. Today’s cell-culture-based vaccines are used in two distinct ways: before a potential exposure (pre-exposure prophylaxis) for people at ongoing risk, and after a bite or scratch from a potentially rabid animal (post-exposure prophylaxis). The vaccine’s track record is remarkably strong, with post-exposure treatment preventing rabies in virtually every case when administered correctly and on time. Yet the picture gets more complicated once you look at who actually receives these vaccines, what side effects to expect, and why tens of thousands of people still die from rabies each year despite having a perfectly good vaccine on the shelf.
A Brief History of the Rabies Vaccine
Louis Pasteur developed the first rabies vaccine in the 1880s, famously demonstrating by 1885 that he had successfully immunized 50 dogs against the virus.1PubMed Central. Louis Pasteur and Dom Pedro II engaged in rabies vaccine development Within a year, the vaccine was available in the United States, and Pasteur Institutes were established across the country to produce and distribute it.2PubMed. The early use of Pasteur’s rabies vaccine in the United States Those early vaccines were made from nerve tissue, which could cause neurological side effects. The World Health Organization has long recommended discontinuing nerve-tissue vaccines in favor of modern cell-culture-derived versions, though a handful of low-income countries still use the older type because of cost and availability constraints.3International Journal of Clinical and Experimental Medical Sciences. Rare Twist: Post-rabies Vaccine Guillain-Barré Syndrome Unveiled
Modern cell-culture vaccines include several formulations you might encounter: human diploid cell vaccine (HDCV), purified chick embryo cell vaccine (PCECV), and purified Vero cell rabies vaccine (PVRV). All of them work by presenting inactivated rabies virus to your immune system, prompting it to produce neutralizing antibodies. The key threshold used worldwide to define an adequate immune response is an antibody level of 0.5 IU/mL or higher.
Pre-Exposure Vaccination
Pre-exposure prophylaxis, often shortened to PrEP, is the kind of vaccination you get before any contact with a potentially rabid animal. It doesn’t make you immune to rabies outright, but it primes your immune system so that if you are bitten, your body responds faster and you need fewer post-exposure doses. The standard schedule involves two or three doses given over a few weeks. A study of the Japanese purified chick embryo cell vaccine found that all 53 subjects had protective antibody levels two weeks after completing a three-dose schedule on days 0, 7, and 28.4PubMed. Pre-exposure immunization against rabies using Japanese rabies vaccine following the WHO recommended schedule
A systematic review and meta-analysis comparing different dose counts and injection routes confirmed that most people who receive two or three doses reach protective antibody levels regardless of whether the vaccine is given into the muscle or just under the skin. One-dose schedules, however, performed significantly worse. Antibody levels do decline over time for all schedules, with two-dose intramuscular schedules losing protection faster than three-dose schedules. The good news is that booster doses reliably bring antibody levels back up to nearly 100% seroconversion, even for people whose primary series was minimal.5PubMed. Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses
Who actually gets pre-exposure vaccination? Veterinarians, wildlife researchers, laboratory workers handling live rabies virus, and people living in areas where rabies is common in animals. Travelers heading to regions with high rabies risk are also advised to consider it, though uptake among travelers is surprisingly low. Among long-term travelers (trips of a month or more) heading to countries where rabies vaccination was strongly recommended, only about 9% actually got vaccinated in one large US study; 30% actively declined.6PubMed Central. Pre-Exposure Rabies Vaccination among US International Travelers: Findings from the Global TravEpiNet Consortium The decision factors that travel clinicians weigh most heavily include how likely the traveler is to encounter animals, whether they are heading to rural or remote areas, and whether reliable medical care is available at the destination.7Travel Medicine and Infectious Disease. Understanding the journey towards rabies vaccination for travellers: Results of a cross-sectional survey with patients and providers in the US, Germany, Sweden, and Switzerland
Post-Exposure Prophylaxis
Post-exposure prophylaxis (PEP) is by far the more common use of the rabies vaccine. More than 29 million people worldwide and roughly 60,000 people in the United States receive PEP every year.8PubMed Central. Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure—Minnesota, 2021 PEP is given after a bite, scratch, or other exposure to an animal that could be carrying rabies. It works because rabies has a relatively long incubation period. The virus usually takes weeks to months to travel from the wound site to the brain, which gives the vaccine time to train the immune system before the virus reaches the point of no return.
For someone who has never been vaccinated, PEP involves two components. First, rabies immunoglobulin (RIG) is injected into and around the wound itself. This provides immediate, temporary protection by neutralizing virus at the bite site before the person’s own immune system kicks in.9PubMed Central. Rabies post-exposure prophylaxis delivery to ensure treatment efficacy and increase compliance Second, a series of vaccine doses is given over two weeks. If you have been previously vaccinated with PrEP, you skip the immunoglobulin and receive only two booster doses, because your immune system already has the memory to mount a rapid response.
An intradermal regimen developed by the Thai Red Cross has been shown to reduce vaccine costs to roughly one-fifth of the standard intramuscular Essen regimen, which typically involves five doses, making PEP more affordable for health systems with large patient volumes.10PubMed Central. Reducing Cost of Rabies Post Exposure Prophylaxis: Experience of a Tertiary Care Hospital in Pakistan The cost matters: in the United States, PEP is expensive, and cost-effectiveness analyses suggest that treatment becomes cost-saving when the probability of actual rabies transmission exceeds about 0.7%.11PubMed. Cost effectiveness of rabies post exposure prophylaxis in the United States For most domestic animal bites in the US, the actual risk is far lower than that, which is why public health officials carefully assess each situation before recommending PEP.
Common Side Effects
Modern rabies vaccines are well tolerated. The side effects people experience most often are local reactions at the injection site: pain, swelling, redness, and mild hardness of the surrounding tissue. How common those reactions are depends partly on the vaccine formulation. According to US CDC data, local reactions occur in roughly 60% to 90% of people receiving human diploid cell vaccine (HDCV) and about 11% to 57% of those receiving purified chick embryo cell vaccine (PCECV).12PubMed Central. A Case of Serious Adverse Reaction Following Rabies Vaccination Most of these reactions are mild and resolve on their own within a few days.
Systemic reactions, meaning symptoms that affect the whole body, include fever, headache, dizziness, and stomach upset. These are less common but not rare. HDCV recipients report systemic reactions at rates between about 7% and 56%, while PCECV recipients report them at rates between 0% and 31%.12PubMed Central. A Case of Serious Adverse Reaction Following Rabies Vaccination A real-world study of over 800 vaccinated patients found fever in about 13% and local pain in about 8%. The vast majority of reactions, over 91%, were graded as mild, and about 63% resolved within 24 to 48 hours. No patients in the study had lasting problems.13PubMed Central. Risk factors for adverse events following rabies vaccination: a multivariate analysis of real-world data
Rare and Serious Adverse Events
Serious reactions to modern cell-culture rabies vaccines are uncommon. The most discussed rare events include allergic reactions and, very infrequently, neurological conditions. One documented case involved a two-year-old girl who developed anaphylaxis after her first dose of HDCV. Investigation revealed that the vaccine batch contained residual kanamycin, an antibiotic she was allergic to. She was switched to a purified Vero cell vaccine with no residues, completed her series without further reactions, and developed an adequate immune response.14PubMed Central. Analysis on the risks of severe adverse events in rabies post-exposure prophylaxis and appropriate decision-making procedure The case is instructive: even when a serious reaction occurs, options exist to complete vaccination safely using a different formulation.
Guillain-Barré syndrome, a condition where the immune system attacks peripheral nerves, has been reported in rare instances following rabies vaccination. The older nerve-tissue vaccines carried a higher risk of neurological complications, which is a major reason the WHO pushed for their replacement.3International Journal of Clinical and Experimental Medical Sciences. Rare Twist: Post-rabies Vaccine Guillain-Barré Syndrome Unveiled With modern cell-culture vaccines, these events are extremely infrequent, and the overwhelming consensus is that the benefit of preventing an almost universally fatal disease far outweighs the risk.
Pregnancy and Immunocompromised Patients
Because rabies is nearly always fatal once symptoms appear, PEP is recommended after a genuine exposure regardless of pregnancy status. A case series in Iran documented pregnant women who received rabies immunoglobulin and vaccine after animal exposures. None of the women or their newborns experienced adverse effects. All infants were born without congenital abnormalities, and most newborns had protective antibody levels, with higher levels seen in newborns whose mothers received more vaccine doses.15PubMed Central. Rabies antibody levels in pregnant women and their newborns after rabies post-exposure prophylaxis
People with suppressed immune systems present a different challenge. A literature search turned up 15 immunocompromised patients who received PEP, and 7 of them did not reach the minimum acceptable antibody level after a full course.16PubMed Central. Inadequate antibody response to rabies vaccine in immunocompromised patient A study of 28 immunocompromised individuals found that 6 had inadequate post-PEP antibody levels, and no single patient characteristic predicted who would fail to respond.17Vaccine. Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies That unpredictability is why the WHO recommends checking antibody levels after PEP in immunocompromised patients, so non-responders can receive additional doses. A smaller study of immunosuppressed patients did find that all cases achieved protective antibody levels after receiving both immunoglobulin and vaccine together, suggesting that the combination offers some buffer.18Archives of Clinical Infectious Diseases. Rabies Neutralizing Antibody Level in Immunosuppressed Patients After Receive of Rabies Post-Exposure Prophylaxis The takeaway for immunocompromised individuals is straightforward: you should still receive PEP after a rabies exposure, but your doctor should verify your immune response with a blood test afterward.
How Rarely Does Post-Exposure Treatment Fail?
When you hear “nearly 100% effective,” it is natural to wonder about the exceptions. A systematic literature review covering 1980 through 2022 identified 124 cases worldwide of people developing rabies after receiving some form of PEP.8PubMed Central. Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure—Minnesota, 2021 Against the backdrop of hundreds of millions of PEP courses administered over those four decades, that is vanishingly rare. And the numbers get even more reassuring when you look at why those failures happened. Deviations from recommended protocols, such as errors in how immunoglobulin was administered, delays in seeking care, or underlying immune problems, were reported in over half the cases.19The Lancet Infectious Diseases. Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures
A more recent analysis applied a stricter definition, counting only cases where PEP was started within two days of exposure and all required components were completed. Of 89 cases meeting their inclusion criteria, only 3 qualified as “true” breakthrough infections, meaning the treatment was given properly and on time, and the patient still developed rabies.20Clinical Infectious Diseases. Rabies Despite Postexposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery? Three cases out of hundreds of millions of treated people. The overwhelming cause of post-PEP rabies is not vaccine failure but breakdowns in how treatment is delivered: starting too late, not getting immunoglobulin into the wound, skipping doses, or not recognizing the exposure in the first place.
Vaccinating Animals to Protect People
The rabies vaccine is not just for humans. Mass vaccination of dogs is the single most cost-effective way to eliminate human rabies in places where the disease is common. Case studies in Tanzania and Bhutan demonstrate that mass canine vaccination programs effectively drove both canine and human rabies down to minimal levels while simultaneously reducing the economic burden of PEP.21PubMed. Rationale and support for a One Health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings
Wildlife vaccination is a separate challenge. In the United States, oral rabies vaccine baits are distributed by helicopter and on the ground to control rabies in wild raccoons, foxes, and coyotes. A campaign on Long Island, New York distributed roughly 1.86 million vaccine baits over five years, using a density of 250 baits per square kilometer, and effectively controlled raccoon rabies in the targeted areas.22PubMed. Oral rabies vaccination strategies toward raccoon (Procyon lotor) rabies elimination on suburban Long Island, New York, USA A pilot program in Kazakhstan recently tested a locally developed briquette-format oral bait across four regions. Uptake was encouraging: about 57% of manually placed baits were consumed. Among free-ranging foxes captured for testing, six out of seven that consumed the bait had protective antibody levels.23PubMed Central. Experimental Immunogenicity and Multi-Region Field Performance of a Briquette-Formulated Oral Rabies Vaccine Bait in Kazakhstan Programs like these represent the front line of global rabies elimination efforts, because you cannot vaccinate every person who might wander near a wild animal, but you can vaccinate enough animals to break the chain of transmission.
Why People Still Die Despite an Effective Vaccine
Rabies kills an estimated 59,000 people a year, almost all of them in Africa and Asia. The paradox is not that the vaccine does not work. It works extraordinarily well. The problem is access. Vaccine supply chain failures lead to stockouts and preventable deaths, even when effective vaccines exist.24PubMed Central. Optimising human rabies vaccine supply chains: A modelling study A study in Tanzania documented the interconnected barriers: recurrent vaccine stockouts, long travel distances (rural patients traveled an average of 34 kilometers versus 13 kilometers for urban patients), and costs that pushed bite victims to abandon PEP, delay treatment, or resort to traditional remedies.25PubMed Central. Practitioner’s perspectives on access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practice These are logistics problems, not science problems. The vaccine itself is solved; getting it to the people who need it is not.
mRNA Rabies Vaccines in Development
The success of mRNA technology during the COVID-19 pandemic naturally raised the question of whether mRNA rabies vaccines could improve on the existing options. The idea is not new: rabies was actually one of the earliest testing grounds for mRNA vaccine technology. A first-in-human trial of an mRNA rabies vaccine (CV7201) delivered by a needle-free device found that about 71% of participants given intradermal doses developed protective antibody levels, though the vaccine did not work well when delivered by ordinary needle and syringe.26The Lancet. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
A subsequent trial tested a lipid-nanoparticle-formulated mRNA vaccine (CV7202) that could be given with a standard syringe. Initial doses of 5 micrograms caused too many side effects, so researchers dropped to 1 and 2 microgram doses, which were better tolerated. After two doses, all recipients in the 1 and 2 microgram groups reached protective antibody levels by day 43, with responses comparable to the established vaccine Rabipur.27PubMed Central. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial Various other mRNA rabies candidates are in clinical and preclinical testing.28PubMed Central. Development of mRNA rabies vaccines The appeal of mRNA platforms includes potentially simpler manufacturing, easier cold-chain requirements, and the possibility of combining rabies with other antigens in a single shot. None of this has made it to market yet, but the early data suggest mRNA rabies vaccines could eventually offer a real alternative.
Monoclonal Antibodies as an Alternative to Immunoglobulin
One of the persistent bottlenecks in PEP is rabies immunoglobulin (RIG), which is derived from human or horse blood, expensive, and frequently unavailable in the countries that need it most. Monoclonal antibodies, lab-manufactured proteins designed to target the rabies virus directly, are being developed as replacements. Research in animal models has shown that a monoclonal antibody called F11 can limit viral load in the brain and even reverse disease signs after the virus has begun replicating in the central nervous system, though full protection required an intact immune response from the host’s own T cells.29PubMed Central. mAb therapy controls CNS‐resident lyssavirus infection via a CD4 T cell‐dependent mechanism A separate study demonstrated that a combination of two human monoclonal antibodies cured symptomatic rabid mice when delivered both peripherally and directly into the brain, leaving recovered animals with undetectable viral loads and nearly normal brain inflammation profiles.30PubMed Central. A combination of two human monoclonal antibodies cures symptomatic rabies These are still preclinical findings, but several monoclonal antibody products have already received regulatory approval in some countries for use alongside the vaccine in PEP, and they could go a long way toward solving the immunoglobulin supply problem.